XSNX NOVACCESS GLOBAL INC
- 0.005750
- -0.001240-17.74%
NOVACCESS GLOBAL INC News
NovAccess Global Announces New License to Advance Its Immunotherapy Platform
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous syste
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de
NovAccess Global Jumps on Announcing $10.7 Million Financing
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th In
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app
NovAccess Global Partners With BCN Biosciences to Expand Immunotherapy Platform
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS TumorsPotential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology MarketCLEVELAND, OH /
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv
NovAccess Global Partners With CKN Ventures to Expand Its New AI-driven Precision Medicine Division
CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Prec
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain TumorsRecent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardCLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developi
Short Interest in NovAccess Global Inc. (OTCMKTS:XSNX) Declines By 52.6%
NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 3,600 shares, a decline of 52.6% fro
NovAccess Global to Present at World Orphan Drug Congress
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dw
NovAccess Global Inc. (OTCMKTS:XSNX) Sees Significant Decrease in Short Interest
NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 3,900 shares, a decline of 25.0% from
Short Interest in NovAccess Global Inc. (OTCMKTS:XSNX) Decreases By 25.0%
NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 3,900 shares, a drop of
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his ContributionsCLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical com
NovAccess Global Announces Fireside Chat With Dr. Christopher Wheeler, the Company's Lead Scientist and President of Its StemVax Therapeutics Division
Topic: Immunotherapy Advantages Over Surgical TreatmentCLEVELAND, OH / ACCESSWIRE / January 5, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brai
NovAccess Global Inc. (OTCMKTS:XSNX) Sees Significant Drop in Short Interest
NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 5,800 shares, a decreas
NovAccess Global Announces Initial Fireside Chat With Glioblastoma Patient Advocate
Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support NetworksCLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomed
NovAccess Global Inc. (OTCMKTS:XSNX) Short Interest Up 97.4% in October
NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 7,700 shares, a growt
Analysis
Price Target
No Data
